



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Intraocular Radiotherapy for Age-Related Macular Degeneration

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 610

BCBSA Reference Number: 9.03.20 (For Plan internal use only)

Related Policies

- Charged-Particle (Proton or Helium Ion) Radiotherapy, #[437](#)
- Intravitreal Angiogenesis Inhibitors for Choroidal Vascular Conditions, #[343](#)
- Photodynamic Therapy for Choroidal Neovascularization, #[599](#)
- Stereotactic Radiosurgery and Stereotactic Body Radiotherapy, #[277](#)
- Transpupillary Thermotherapy for Treatment of Choroidal Neovascularization, #[600](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Intraocular placement of a radiation source (brachytherapy) for the treatment of choroidal neovascularization is [INVESTIGATIONAL](#).

Proton beam therapy for the treatment of choroidal neovascularization is [INVESTIGATIONAL](#).

Stereotactic radiotherapy for the treatment of choroidal neovascularization is [INVESTIGATIONAL](#).

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is not a covered service.
Commercial PPO and Indemnity	This is not a covered service.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

CPT Codes

There are not any specific codes for this procedure

Description

Age-Related Macular Degeneration

Age-related macular degeneration is the leading cause of legal blindness in individuals older than age 60 in developed nations. Age-related macular degeneration is characterized in its earliest stages by minimal visual impairment and the presence of large drusen and other pigmentary abnormalities on ophthalmoscopic examination. Two distinctive forms of degeneration may be observed. The first, called the atrophic or areolar or dry form, evolves slowly. Atrophic age-related macular degeneration is the most common form of degeneration and may be a precursor of the more visually impairing exudative neovascular form, also referred to as disciform or wet age-related macular degeneration. The wet form is distinguished from the atrophic form by the development of choroidal neovascularization and serous or hemorrhagic detachment of the retinal pigment epithelium. Risk of developing severe irreversible loss of vision is greatly increased by the presence of choroidal neovascularization.

Standard Clinical Management

Usual care for neovascular age-related macular degeneration includes intravitreal agents that target vascular endothelial growth factor, including pegaptanib, ranibizumab, bevacizumab, and aflibercept. Photodynamic therapy is an older method that has been largely replaced by anti-vascular endothelial growth factor therapies. The intravitreal therapies may necessitate repeated intravitreal injections. Hence, alternative treatments, such as intraocular radiation, including brachytherapy, proton beam therapy, and stereotactic radiotherapy, are being investigated.

Intraocular Radiotherapy

The NeoVista Epi-Rad90 Ophthalmic System, a brachytherapy device, treats choroidal neovascularization by delivering focal radiation to a subfoveal choroidal neovascular lesion. Using a standard vitrectomy procedure, the cannula tip of a handheld (pipette-like) surgical device is inserted into the vitreous cavity and positioned under visual guidance over the target lesion. The radiation source (strontium 90) is advanced down the cannula until it reaches the tip, which is then held in place over the lesion for a "prescribed" time to deliver focused radiation. The system is designed to deliver a 1-time peak dose of beta particle energy (24 gray) for a target area 3 mm in depth and up to 5.4 mm in diameter. This dose is believed to be below that toxic to the retina and optic nerve. Radiation exposure outside of the target area is expected to be minimal.

Proton beam therapy is a type of external radiotherapy that uses charged atomic particles (protons or helium ions) to target a given area. Proton beam therapy differs from conventional electromagnetic (photon) radiotherapy in that, with proton beam therapy, there is less scatter as the particle beams pass through tissue to deposit ionizing energy at precise depths (Bragg peak). The theoretical advantage of proton beam therapy over photon therapy is the ability to deliver higher radiation doses to the target without harm to adjacent normal tissue.

Stereotactic radiotherapy is a nonsurgical procedure performed in an office setting. It uses a robotically controlled device to deliver radiation beams through the inferior sclera to overlap at the macula.

Summary

Intraocular radiation, including brachytherapy, proton beam therapy, and stereotactic radiotherapy, are being evaluated to treat choroidal neovascularization associated with age-related macular degeneration.

For individuals who have choroidal neovascularization due to age-related macular degeneration who receive brachytherapy, the evidence includes 2 randomized controlled trials (RCTs) comparing brachytherapy plus vascular endothelial growth factor with vascular endothelial growth factor monotherapy as well as phase 1/2 trials and case series on the use of brachytherapy. Relevant outcomes are change in disease status, morbid events, functional outcomes, quality of life, medication use, and treatment-related morbidity. Both RCTs showed that brachytherapy did not attain noninferiority for visual acuity outcomes and was associated with a higher proportion of adverse events. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have choroidal neovascularization due to age-related macular degeneration who receive proton beam therapy, the evidence includes a randomized, prospective, sham-controlled trial and a pilot study. Relevant outcomes are change in disease status, morbid events, functional outcomes, quality of life, medication use, and treatment-related morbidity. Recruitment into the RCT was halted for ethical concerns, and available results did not show statistically significant stabilization of visual acuity. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have choroidal neovascularization due to age-related macular degeneration who receive stereotactic radiotherapy, the evidence includes an RCT with sham control. Relevant outcomes are change in disease status, morbid events, functional outcomes, quality of life, medication use, and treatment-related morbidity. The RCT showed a reduction in the number of vascular endothelial growth factor treatments at 12- and 24-month intervals, but no significant differences vs controls for changes in visual acuity. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
4/2022	Annual policy review. Policy statements unchanged.
4/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference.
5/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
4/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2019	Clarified coding information.
4/2017	Annual policy review. New references added.
5/2016	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
3/2015	Annual policy review. New references added.
7/2014	Annual policy review. New investigational indications described; title changed. Effective 7/1/2014.
8/2013	Annual policy review. New investigational indications described; title changed. Effective 8/1/2013.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
5/2011	New policy describing ongoing non-coverage.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Evans JR, Igwe C, Jackson TL, et al. Radiotherapy for neovascular age-related macular degeneration. *Cochrane Database Syst Rev*. Aug 26 2020; 8: CD004004. PMID 32844399
2. Jackson TL, Desai R, Simpson A, et al. Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial. *Ophthalmology*. Jun 2016; 123(6): 1287-96. PMID 27086023
3. Jackson TL, Soare C, Petrarca C, et al. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial. *JAMA Ophthalmol*. Aug 01 2020; 138(8): 835-842. PMID 32644148
4. Dugel PU, Bebchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). *Ophthalmology*. Feb 2013; 120(2): 317-27. PMID 23174399
5. Jackson TL, Dugel PU, Bebchuk JD, et al. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. *Ophthalmology*. Aug 2013; 120(8): 1597-603. PMID 23490325
6. Dugel PU, Petrarca R, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results. *Ophthalmology*. Jul 2012; 119(7): 1425-31. PMID 22465819
7. Petrarca R, Dugel PU, Nau J, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography. *Ophthalmology*. Feb 2013; 120(2): 328-33. PMID 23178157
8. Petrarca R, Dugel PU, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results. *Retina*. May 2014; 34(5): 874-9. PMID 24169101
9. Avila MP, Farah ME, Santos A, et al. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. *Retina*. Feb 2009; 29(2): 157-69. PMID 19202425
10. Avila MP, Farah ME, Santos A, et al. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. *Br J Ophthalmol*. Mar 2009; 93(3): 305-9. PMID 19019935
11. Avila MP, Farah ME, Santos A, et al. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Retina*. Jan 2012; 32(1): 10-8. PMID 21817963
12. Park SS, Daftari I, Phillips T, et al. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration. *Retina*. May 2012; 32(5): 956-66. PMID 22183743
13. Ciulla TA, Danis RP, Klein SB, et al. Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. *Am J Ophthalmol*. Dec 2002; 134(6): 905-6. PMID 12470761
14. Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. *Ophthalmology*. Sep 2013; 120(9): 1893-900. PMID 23490327
15. Jackson TL, Chakravarthy U, Slakter JS, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study. *Ophthalmology*. Jan 2015; 122(1): 138-45. PMID 25208859
16. Ranjbar M, Kurz M, Holzhey A, et al. Stereotactic radiotherapy in neovascular age-related macular degeneration: Real-life efficacy and morphological evaluation of the outer retina-choroid complex. *Medicine (Baltimore)*. Dec 2016; 95(52): e5729. PMID 28033280
17. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern: Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015.

18. American Academy of Ophthalmology. Age-related macular degeneration. Preferred practice pattern. October 2019. <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp>. Accessed February 2, 2021.
19. National Institute for Health and Care Excellence. Epiretinal brachytherapy for wet age-related macular degeneration [IPG415]. 2011; <https://www.nice.org.uk/guidance/IPG415>. Accessed February 2, 2021.